Telomir Pharmaceuticals Inc

Telomir Pharmaceuticals Inc operates with a capital structure that is entirely equity-funded, as evidenced by a debt-to-equity ratio of 0.00 and no long-term debt. The company's liquidity position is strong, with a current ratio of 7.2, indicating that it holds significantly more current assets than current liabilities. However, the company's valuation is highly inflated relative to its tangible book value, with a price-to-tangible-book ratio of 14.47.

The company's profitability metrics are negative, with a return on equity of -2.07% and a return on assets of -1.79%, both of which are below the typical thresholds for industry-leading performance. These figures suggest that Telomir is not generating returns that meet the cost of capital, which is a concern for investors seeking capital appreciation.

Telomir's revenue concentration is not disclosed in the available data, but the absence of revenue in the latest financial snapshot indicates that the company is in an early stage of development or has not yet commercialized its products. The company's geographic exposure is also not specified, but the lack of revenue suggests that it may not have a broad market presence.

The company's growth trajectory is uncertain, as the latest financial data shows no revenue and a net loss of $6.25 million. Analysts have set a mean price target of $15.50, which is significantly higher than the current market price of $1.27, but this is based on limited financial performance data. The absence of revenue and the negative net income suggest that the company is in a pre-revenue or early-stage development phase.

The risk assessment for Telomir indicates low liquidity and dilution risk, with no immediate filing-based flags detected. However, the company's negative net income and operating cash flow of -$1.94 million suggest that it may require additional capital in the near future. The dilution potential is currently low, but the company's reliance on equity financing could increase if it needs to raise more capital to fund operations.

Recent events and filings do not provide specific details on Telomir's operations or strategic direction, but the company's financial snapshot indicates that it is in a development phase with no revenue generation. The absence of revenue and the negative net income suggest that the company is focused on research and development rather than commercial operations.

Analysts project a mean price target of $15.50, implying significant upside potential from the current market price of $1.10.

The company maintains a strong liquidity position with a current ratio of 5.14, indicating ample short-term assets to cover liabilities.

Telomir Pharmaceuticals operates with low leverage, evidenced by a debt-to-equity ratio of 0.24 and minimal long-term debt obligations.

The firm faces low dilution risk, suggesting that existing shareholders are less likely to experience significant equity value erosion from new issuances.

Liquidity risk is assessed as low, providing the company with sufficient financial flexibility to manage its operational cash flow needs.

The company reported a net loss of $10.4 million in fiscal year 2026, highlighting its inability to generate profitable operations.

Telomir Pharmaceuticals generates zero revenue, indicating a complete lack of commercial product sales or recurring income streams.

Return on equity stands at -2.07%, placing the company in the bottom quartile compared to its pharmaceutical peer cohort.

The firm carries a high credit risk flag, signaling potential difficulties in meeting financial obligations or securing favorable financing terms.

Revenue $0.00; Operating income +26,5% YoY.

• ▍Revenue $0.00
• ▍Operating income +26,5% YoY
• ▍Net income +28,9% YoY

Revenue $0.00; Operating income +80,9% YoY.

• ▍Revenue $0.00
• ▍Operating income +80,9% YoY
• ▍Net income +81,6% YoY

Revenue $0.00; Operating income −243,8% YoY.

• ▍Revenue $0.00
• ▍Operating income −243,8% YoY
• ▍Net income −249,9% YoY

Revenue $0.00; Operating income −14,2% YoY.

• ▍Revenue $0.00
• ▍Operating income −14,2% YoY
• ▍Net income +65,2% YoY

Revenue $0.00; Operating income -$2.9M.

• ▍Revenue $0.00
• ▍Operating income -$2.9M

Revenue $0.00; Operating income +13,9% YoY.

• ▍Revenue $0.00
• ▍Operating income +13,9% YoY
• ▍Net income +37,0% YoY

Revenue $0.00; Operating income −7,1% YoY.

• ▍Revenue $0.00
• ▍Operating income −7,1% YoY
• ▍Net income −26,5% YoY